Literature DB >> 9569170

What is the economic case for treating obesity?

A M Wolf1.   

Abstract

From both societal and payer perspectives, the economic effect of obesity in the United States is substantial, estimated at approximately 6% of our national health expenditure and cost of care in a major health maintenance organization. The number of physician visits related to obesity has increased 88% in a 6-year period. The morbidity cost (lost productivity) and functional capability of the patient with obesity is increasing rapidly (50% increase in lost productivity, 36% increase in restricted activity, and 28% increase in number of bed-days). Cost savings of treating obesity are comparable to those of treating other chronic diseases such as coronary heart disease and diabetes. Most studies indicate that most of the direct health care costs of obesity are from type 2 diabetes, coronary heart disease and hypertension. To date, however, there have been no published reports of the cost effectiveness of the medical management of obesity treatment. In conclusion, the cost of obesity is comparable to that of other chronic diseases, yet it receives disproportionately less attention. Cost effectiveness studies need to be initiated promptly.

Entities:  

Mesh:

Year:  1998        PMID: 9569170     DOI: 10.1002/j.1550-8528.1998.tb00682.x

Source DB:  PubMed          Journal:  Obes Res        ISSN: 1071-7323


  19 in total

1.  Prevention and treatment of childhood obesity.

Authors:  C L Williams; M T Gulli; R J Deckelbaum
Journal:  Curr Atheroscler Rep       Date:  2001-11       Impact factor: 5.113

2.  A cost-benefit analysis of bariatric surgery on the South Plains region of Texas.

Authors:  Bradley T Ewing; Mark A Thompson; Mitchell S Wachtel; Eldo E Frezza
Journal:  Obes Surg       Date:  2011-05       Impact factor: 4.129

3.  Early results with a new telemetrically adjustable gastric banding.

Authors:  Rudolf A Weiner; Michael Korenkov; Esther Matzig; Sylvia Weiner; Woiteck K Karcz; Theodor Junginger
Journal:  Obes Surg       Date:  2007-06       Impact factor: 4.129

4.  Intragastric injection of botulinum toxin for the treatment of obesity. Where are we?

Authors:  Diego Garcia-Compean; Hector Maldonado Garza
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

5.  The economic impact of morbid obesity.

Authors:  Eldo E Frezza; Mitchell S Wachtel
Journal:  Surg Endosc       Date:  2009-01-30       Impact factor: 4.584

6.  Why U.S. health care expenditure and ranking on health care indicators are so different from Canada's.

Authors:  A H G M Spithoven
Journal:  Int J Health Care Finance Econ       Date:  2008-07-01

7.  Long-term obesity and avoidable hospitalization among younger, middle-aged, and older adults.

Authors:  Markus H Schafer; Kenneth F Ferraro
Journal:  Arch Intern Med       Date:  2007-11-12

Review 8.  Direct medical cost of overweight and obesity in the USA: a quantitative systematic review.

Authors:  A G Tsai; D F Williamson; H A Glick
Journal:  Obes Rev       Date:  2011-01       Impact factor: 9.213

9.  Estimating prevalence of overweight and obesity at the neighborhood level: the value of maternal height and weight data available on birth certificate records.

Authors:  David A Webb; Jessica M Robbins; Joan R Bloch; Jennifer F Culhane
Journal:  Popul Health Metr       Date:  2010-05-25

10.  Gender-specific disparities in obesity.

Authors:  Tyrone F Borders; James E Rohrer; Kathryn M Cardarelli
Journal:  J Community Health       Date:  2006-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.